Immunotherapies in rare cancers

HIGHLIGHTS

• who: Sneha Vivekanandhan from the in , diffuse type tenosynovial giant cell tumor patients treated with emactuzumab showed favorable responsesBiopsy tissues were available for , patients, and these demonstrated a significant decrease in CSF R+ and CD68/CD163+ macrophages. Independently the overall objective response rate (ORR) was high at, %. Additionally, the responses were durable with an ORR of , and, % after one and , years post enrollment into the study, respectively [56]. A third approach to macrophage modulation, chimeric antigen receptor (CAR)-T cell-mediated TAM modulation was recently described in an ovarian cancer pre-clinical model. The authors used CAR . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.